◎ Sugi Atlas

Atlas / Disease / Tricuspid valve disorder

Tricuspid valve disorder

disease
On this page

Also known as disease of tricuspid valvedisease or disorder of tricuspid valvedisorder of tricuspid valveRH. tricuspid valve diseaserheumatic disease of tricuspid valverheumatic tricuspid valve diseasetricuspid valve diseasetricuspid valve disease or disorder

Summary

Tricuspid valve disorder (MONDO:0000471) is a disease with 10 GWAS associations across 13 studies and 24 clinical trials. Top therapeutic interventions include acetaminophen and hexachlorophene. A subtype of heart valve disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • GWAS associations: 10
  • Clinical trials: 24

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nametricuspid valve disorder
Mondo IDMONDO:0000471
EFOEFO:0009568
DOIDDOID:0050826
ICD-111843615838
NCITC78649
SNOMED CT20721001
UMLSC0264882
MedGen120507
Anatomy (UBERON)UBERON:0002134
Is cancer (heuristic)no

Also known as: disease of tricuspid valve · disease or disorder of tricuspid valve · disorder of tricuspid valve · RH. tricuspid valve disease · rheumatic disease of tricuspid valve · rheumatic tricuspid valve disease · tricuspid valve disease · tricuspid valve disease or disorder · tricuspid valve disorder

Data availability: 10 GWAS associations (13 studies).

Disease family

This is a subtype of heart valve disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › heart valve disorder › tricuspid valve disorder

Related subtypes (3): pulmonary valve disorder, mitral valve disorder, aortic valve disorder

Subtypes (4): tricuspid valve insufficiency, tricuspid valve stenosis, congenital tricuspid malformation, cleft leaflet of tricuspid valve

Genetics & variants

GWAS landscape

10 GWAS associations across 13 studies. Top hits map to 5 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs5487488563e-15KIF26BG4.11
rs5617081652e-13TNFSF4A2
rs5740231454e-13AEBP2C4.27
rs5314577188e-13LINC03101 - CTDP1-DTG3.59
rs5412042448e-13EDN3 - PIEZO1P1T4.86
rs5650123291e-12SRD5A2G2.91
rs5493234464e-12RN7SKP93 - MGAT5G3.12
rs562352444e-12MTCO1P6 - U3C2.95
rs1907805041e-11DPPA3P9 - LINC01419T3.51
rs1478019224e-08UBA6-DT?

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90473512UK Biobank Whole-Genome Sequencing Consortium20251,883456,557Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90477843Verma A20241,694442,596Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477835Verma A20241,353443,776Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436057Zhou W20181,058402,421Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90473559UK Biobank Whole-Genome Sequencing Consortium2025682457,758Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90480121Verma A2024421119,723Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481971Verma A2024421119,723Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480119Verma A2024353119,899Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481969Verma A2024353119,899Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90726892Kim HI202621343,813Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic10

MAF distribution

BucketVariants
common (>=0.05)0
low_freq (0.01-0.05)0
rare (<0.01)9
unknown1

Functional consequences

ConsequenceCount
intron_variant5
intergenic_variant5

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs5487488561245386795G>A0.001intron_variantKIF26B3e-15Tier 4: intronic/intergenic
rs5617081651173409694A>C0.002intron_variantTNFSF42e-13Tier 4: intronic/intergenic
rs5740231451219532015C>A,T0intergenic_variantAEBP24e-13Tier 4: intronic/intergenic
rs5314577181879631151G>A0intron_variantLINC03101 - CTDP1-DT8e-13Tier 4: intronic/intergenic
rs5412042442059459877T>C0.001intergenic_variantEDN3 - PIEZO1P18e-13Tier 4: intronic/intergenic
rs565012329231569369G>T0intron_variantSRD5A21e-12Tier 4: intronic/intergenic
rs5493234462133671178G>A0intergenic_variantRN7SKP93 - MGAT54e-12Tier 4: intronic/intergenic
rs56235244389673039C>G,T0intergenic_variantMTCO1P6 - U34e-12Tier 4: intronic/intergenic
rs190780504883255323T>A0intergenic_variantDPPA3P9 - LINC014191e-11Tier 4: intronic/intergenic
rs147801922467713821C>Tintron_variantUBA6-DT4e-08Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 24.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified24

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02397668Not specifiedRECRUITINGCorMatrix Cor TRICUSPID ECM Valve Replacement Study
NCT04097145Not specifiedRECRUITINGEdwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
NCT04482062Not specifiedACTIVE_NOT_RECRUITINGTRISCEND II Pivotal Trial
NCT05064514Not specifiedACTIVE_NOT_RECRUITINGInvestigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease
NCT05742906Not specifiedRECRUITINGCorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study
NCT05797519Not specifiedRECRUITINGClinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation
NCT05848284Not specifiedRECRUITINGClinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
NCT05913908Not specifiedRECRUITINGEFS of the DUO System for Tricuspid Regurgitation
NCT05961150Not specifiedRECRUITINGPROMISE: Percutaneous peRipheral cannulatiOn for Minimally-InvaSive Heart Valve surgEry
NCT06001489Not specifiedRECRUITINGThe Effects of 360-degree Virtual Reality on Pre-procedural Anxiety in Patients Awaiting Elective Cardiac Surgery Involving a Sternotomy
NCT06137807Not specifiedRECRUITINGTRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06235385Not specifiedRECRUITINGEuropean Association of Cardiovascular Imaging Multiple and Mixed Valvular Disease Study
NCT06458907Not specifiedNOT_YET_RECRUITINGPivotal Trial to Evaluate the Safety and Effectiveness of the P&F TricValve® Transcatheter Bicaval Valve System
NCT06591000Not specifiedRECRUITINGClinical Efficacy and Long-term Outcomes of ALLOgraft Versus Stented Biological Prosthesis for Primary TRIcuspid Valve Disease (ALLOTRI)
NCT07267117Not specifiedRECRUITINGCohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
NCT07516444Not specifiedNOT_YET_RECRUITINGVDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)
NCT07552272Not specifiedNOT_YET_RECRUITINGHummingbird ICE Study
NCT02505074Not specifiedUNKNOWNNatural History of Melody Valve in the Mitral and Tricuspid Position
NCT03239262Not specifiedCOMPLETEDLeft Atrial Cryoablation Enhanced by Ganglionated Plexi Ablation in the Treatment of Atrial Fibrillation
NCT03546231Not specifiedUNKNOWNCharacteristics and Prognosis of Moderate or Severe Tricuspid Regurgitation
NCT03859102Not specifiedUNKNOWNEnhanced Recovery After Cardiac Surgery
NCT04231461Not specifiedCOMPLETEDQuality of Life After Cardiac Surgery
NCT04665583Not specifiedTERMINATEDPrehab Prior to Undergoing Tricuspid Intervention
NCT04950192Not specifiedCOMPLETEDPhilips Intracardiac Echocardiography (ICE) Clinical Registry

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
ACETAMINOPHEN41
HEXACHLOROPHENE41

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 23

This page pulls from 23 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardbsnpdoidefogenccgwasgwas_studyhgncicd11medgenmeshmimmondomondochildmondoparentncitorphanetsctiduberonumls